New chemo rotation may shrink pancreatic tumors enough for surgery
NCT ID NCT07043270
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 29 times
Summary
This study tests whether switching between two different chemotherapy combinations can help people with borderline resectable pancreatic cancer. The goal is to shrink the tumor enough for successful surgery and to improve survival without the cancer coming back. About 35 adults will receive alternating cycles of gemcitabine plus nab-paclitaxel and mFOLFIRINOX before any surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREAS ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dartmouth-Hitchcock Medical Center
RECRUITINGLebanon, New Hampshire, 03756, United States
Conditions
Explore the condition pages connected to this study.